Post

New research · Geriatrics
Drugs & aging · 1w
ReviewDrugs & aging · 2026

Caring for Older Adults with Acute Myeloid Leukemia: Best Practices for Aligning Patient Fitness and Preference with Available Therapies.

Stephanie Franco, Christopher Wanjiku, Daniel R Richardson
Read paper
GeriatricsReview

Older adults with acute myeloid leukemia survive about 15 months despite best therapies

Caring for Older Adults with Acute Myeloid Leukemia: Best Practices for Aligning Patient Fitness and Preference with Available Therapies.

Stephanie Franco … Daniel R Richardson
Drugs & aging · 2026
Background

Major advances in drug development and supportive care have led to a paradigm shift in the management of many of the aspects of clinical care for older adults with acute myeloid leukemia.

15
Results
15
months
Half of these older patients die within about 15 months, even when treated
More results

Five-year survival for adults over the age of 75 years is profoundly low, below 10%.

For many patients, current therapies fail to dramatically extend life or improve the quality of life.

These stark realities must inform clinical decision making and fuel further research.

More results

This review critically examines current treatment options including recently approved targeted agents in the upfront and relapsed setting including FLT3 inhibitors, isocitrate dehydrogenase 1/2 inhibitors, and the newly approved menin inhibitors.

“
Conclusion

We also introduce theory-driven preference assessments that are increasingly being used to capture patient treatment outcome priorities.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
33.3%
more treated eyes could see at least 20/150 by follow-up
Study
70%
degenerative holes had complete loss of the outer light-sensing retinal layers
Cohort Study
1.25 vs 1.90 logMAR
initial vision was better for patients who achieved better final eyesight
Cohort Study
HR = 3.12
Patients positive for both markers had about 3 times the progression rate
Cohort Study
16.46
average everyday-function score three months after surgery, up from before, meaning better function
Study
8 questions
key research questions identified for lower leg soft-tissue injuries in older adults